BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in Equity Research Report

INmune Bio (NASDAQ: INMB), a biotechnology company focused on modulating components of the innate immune system to treat cancers and chronic neurological diseases, was featured in an equity research report by Quantum Media Group LLC. Quantum announced its coverage initiative on INmune Bio on Dec. 30, 2020, and provided details on its research paper that discusses the paradigm shift in Alzheimer’s research and treatment strategies in development, rejecting the decades-long approach by the pharmaceutical industry and academia at large. Quantum believes that INmune Bio’s XPro1595 is potentially a best-in-class Alzheimer’s drug, and further believes that the readout for the upcoming clinical trial will be encouraging. The report reads, “We believe that a company called INmune Bio (NASDAQ: INMB) is most likely to benefit from this transition away from the amyloid beta hypothesis, and that it positions itself at the forefront of this new paradigm with a best-in-class antiinflammatory, non-immune suppressing drug. Furthermore, we believe INmune may be significantly undervalued and that its Alzheimer’s drug has a significant chance to show significant clinical benefit in Alzheimer’s patients, which would be nothing short of a massive medical breakthrough as there are no approved drugs that modify the disease progression; the only drugs that exist to treat Alzheimer’s simply treat the symptoms.”

To view the full report, visit https://ibn.fm/vFPDg

About INmune Bio Inc.

INmune Bio is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor(TM)), cancer (INB03(TM)), Alzheimer’s (XPro1595), and NASH (LIVNate(TM)). The Natural Killer Cell Priming Platform includes INKmune(TM), aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork